ARS Pharmaceuticals (SPRY) Share-based Compensation (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Share-based Compensation of $65.0 million for Q1 2026, up 12364.15% sequentially from -$530000.0 in Q4 2025, and up 1126.88% YoY from $5.3 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Share-based Compensation (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Share-based Compensation for 7 years, with the latest figure at $65.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 1126.88% year-over-year to $65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.0 million (up 502.63% YoY) and the FY2025 annual result came in at $42.4 million, up 3.16% from the prior year.
- Share-based Compensation advanced to $65.0 million in Q1 2026 per SPRY's latest filing, from -$530000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $65.0 million in Q1 2026 and troughed at -$530000.0 in Q4 2025.
- A 5-year average of $5.8 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1953.49% in 2025, down 112.43% in 2025.
- Over 5 years, Share-based Compensation stood at $4.8 million in 2022, then slumped by 52.17% to $2.3 million in 2023, then surged by 87.14% to $4.3 million in 2024, then plunged by 112.43% to -$530000.0 in 2025, then jumped by 12364.15% to $65.0 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $65.0 million, -$530000.0, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 46.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.90 Mn |
| Jun 30, 2026 | 46.90 Mn |
| Mar 31, 2026 | 65.00 Mn |
| Mar 31, 2026 | 65.00 Mn |
| Dec 31, 2025 | -530,000.00 |
| Dec 31, 2025 | -530,000.00 |
| Sep 30, 2025 | 5.69 Mn |
| Sep 30, 2025 | 5.69 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Sep 30, 2024 | 680,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Mar 31, 2024 | 258,000.00 |
| Mar 31, 2024 | 258,000.00 |